Abstract:Key PointsMost heat-shock proteins (HSPs) are constitutively expressed molecular chaperones that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth and survival. Their levels of intracellular expression increase in response to protein-denaturing stressors, such as temperature change, as an evolutionarily conserved response to restore the normal protein-folding environment and to enhance cell survival.The essential chaperoning functions of HSPs are subverted during oncogenesis to make malignant transformation possible and to facilitate rapid somatic evolution.Functioning as biochemical buffers for the numerous genetic lesions that are present within tumours, chaperones, especially HSP90, allow mutant proteins to retain or even gain function while permitting cancer cells to tolerate the imbalanced signalling that such oncoproteins create.Highly specific inhibitors of HSP90 have been identified that redirect its chaperoning activity and decrease cellular levels of the many cancer-related client proteins that depend on it for their function.The use of HSP90 inhibitors has proven invaluable at a basic level in probing the complex cellular functions of this chaperone.The modulation of client protein levels has been demonstrated in animal models and cancer patients following systemically well-tolerated exposure to the HSP90 inhibitor 17AAG, which is the first in its class.Work is ongoing to identify and develop new HSP90 inhibitors with improved pharmacological properties.The best way to exploit the novel mechanism of action of HSP90 inhibitors for anticancer therapy remains to be defined, but probably involves combination with conventional cytotoxic drugs or other molecularly targeted agents.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of chaperone proteins (especially heat shock protein 90, HSP90) in the occurrence and development of cancer, and to study the potential of interfering with the function of HSP90 by pharmacological means as an anti - cancer treatment strategy. Specifically, the paper focuses on the following points: 1. **Basic biological functions of chaperone proteins**: Chaperone proteins are responsible for guiding the normal folding of proteins, intracellular localization and protein degradation within cells. They play a crucial role in maintaining intracellular protein homeostasis. 2. **The role of HSP90 in cancer**: HSP90 is not only involved in the normal folding and maturation of key regulators of cell growth, differentiation and survival, but also exploited by malignant transformation during tumorigenesis, helping cancer cells adapt to the harsh microenvironment and promoting rapid somatic evolution. In addition, HSP90 enables cancer cells to tolerate internal gene mutations, which may be fatal in other cases but contribute to cancer development here. 3. **The potential of HSP90 as an anti - cancer treatment target**: The paper discusses how small - molecule drugs targeting HSP90 can disrupt the activities of multiple receptors, kinases and transcription factors, which are known to be related to the occurrence of cancer. By redirecting the chaperone activity of HSP90, these drugs reduce the cellular levels of many cancer - related client proteins that depend on it, showing a unique prospect as an anti - cancer treatment. 4. **Clinical development of HSP90 inhibitors**: The paper also outlines the current status of clinical development of HSP90 inhibitors and their prospects as effective cancer chemotherapeutic drugs. In particular, the first - generation HSP90 inhibitor 17 - AAG has been proven to effectively reduce client protein levels in animal models and cancer patients, and is well - tolerated for systemic administration. In summary, this paper aims to deeply understand the mechanism of HSP90 in cancer and explore the possibility of using it as a new target for anti - cancer treatment.

HSP90 and the chaperoning of cancer

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

Inhibitors of the HSP90 Molecular Chaperone: Current Status

HSP90 multi-functionality in cancer

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

Targeting chaperones in transformed systems – a focus on Hsp90 and cancer

The Hsp90 molecular chaperone: an open and shut case for treatment

Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials

HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy

Evolutionarily Conserved Dual Lysine Motif Determines the Non-Chaperone Function of Secreted Hsp90alpha in Tumour Progression

Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer

Extracellular heat shock protein 90 alpha (eHsp90α)'s role in cancer progression and the development of therapeutic strategies

Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

Heat Shock Protein 90 in Neurodegenerative Diseases

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects

Therapeutic and diagnostic implications of Hsp90 activation